Imojev 0.5 ml/vial sc injection
Generic: Encephalitis Vaccine
Company: Synovia Pharma PLC.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Generic: Encephalitis Vaccine
Company: Synovia Pharma PLC.. Prices are as listed on BestinMeds; your pharmacy price may differ.
Reviewed by: not listed yet. Source: not listed yet.
Last updated September 7, 2024.
Sorted by price per sc injection. Ask your pharmacist before you switch brands.
Prices as listed on BestinMeds.
No price is listed for this strength yet.
Advertisement
What this medicine is for, how to take it, and what to watch for.
Read the full Encephalitis Vaccine guide
Encephalitis virus vaccine Encephalitis Vaccine is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older. Encephalitis Vaccine should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.
Adults (18 to ≤ 65 years of age): The primary vaccination series consists of two separate doses of 0.5 ml each, according to the following conventional schedule: First dose: Day 0. Second dose: 28 days after first dose. Rapid schedule: Persons aged 18 to ≤65 years can be vaccinated in a rapid schedule as follows: First dose: Day 0. Second dose: 7 days after first dose. With both schedules, primary immunisation should be completed at least one week prior to potential exposure to Japanese encephalitis virus (JEV). It is recommended that vaccinees who received the first dose of Encephalitis Vaccine complete the primary 2-dose vaccination course with Encephalitis Vaccine. If the primary immunization of two injections is not completed, full protection against the disease might not be achieved. There is data that a second injection given up to 11 months after the first dose results in high seroconversion rates. Booster dose: A booster dose (third dose) should be given within the second year (i.e. 12-24 months) after primary immunization, prior to potential re-exposure to JEV. Persons at continuous risk for acquiring Japanese encephalitis (laboratory personnel or persons residing in endemic areas) should receive a booster dose at month 12 after primary immunization. Long-term seroprotection data following a first booster dose administered 12-24 months after primary immunization suggest that a second booster should be given 10 years after the first booster dose, prior to potential exposure to JEV. Elderly (>65 years of age): The primary vaccination series consists of two separate doses of 0.5 ml each, according to the following conventional schedule: First dose: Day 0. Second dose: 28 days after first dose. Pediatric Population: Children and adolescents from 3 years to
Very common: headache, muscle pain, injection site pain, injection site tenderness, tiredness. Common: Nausea, influenza like illness, fever, other injection site reactions (e.g. redness, hardening, swelling, itching). Uncommon: vomiting, skin rash, changes in the lymph-nodes, migraine (throbbing headache, often accompanied by nausea and vomiting and sensitivity to light), dizziness, vertigo (spinning sensation), diarrhoea, belly pain, excessive sweating, itching, chills, general condition of feeling unwell, musculoskeletal stiffness, joint pain, weakness, abnormal laboratory liver test results (hepatic enzymes increased).
Have appropriate medical treatment (including epinephrine) available in the event of a rare anaphylactic reaction following administration of Encephalitis Vaccine.Defer administration of Encephalitis Vaccine in individuals with moderate or severe acute illness until they have recovered.Use caution in individuals with a history of egg allergy or gelatin allergy, as some Encephalitis Vaccine presentations are manufactured using egg-based substrates or contain gelatin stabilizer; consult the specific product label.Encephalitis Vaccine does not provide 100% protection; travelers should also be counseled on mosquito-bite avoidance measures.See Contraindications for individuals in whom Encephalitis Vaccine must not be given, and Use in Special Populations for guidance on immunocompromised individuals.
Pregnancy: There are limited amount of data from the use of Encephalitis Vaccine in pregnant women. In animal studies findings of unclear clinical relevance have been identified. As a precautionary measure, the use of Encephalitis Vaccine during pregnancy should be avoided. Breast-feeding: It is unknown whether Encephalitis Vaccine is excreted in human milk. No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-feeding woman to Encephalitis Vaccine is negligible. However, in the absence of data and as a precautionary measure the use of Encephalitis Vaccine during lactation should be avoided. Fertility: A study in rats did not indicate vaccine-related effects on female reproduction, foetal weight, survival and development of the off-spring.
The mechanism of action of Japanese encephalitis (JE) vaccines is not well understood. Studies in animals have shown that the vaccine triggers the immune system to produce antibodies against Japanese encephalitis virus that are most often protective. Challenge studies were performed in mice that were treated with human Encephalitis Vaccine antisera. These studies showed that almost all mice that had a Plaque Reduction Neutralization Test titre of at least 1:10 were protected from a lethal Japanese encephalitis virus challenge.
Encephalitis Vaccine may be administered concomitantly with other age-appropriate inactivated or live vaccines, at separate injection sites, in accordance with national immunization schedules.Immunosuppressive therapy (corticosteroids, chemotherapy, biologics): may reduce the immune response to Encephalitis Vaccine; immunocompromised individuals may have a suboptimal antibody response, and live-attenuated formulations should generally be deferred in significantly immunosuppressed individuals (see Contraindications).Immunoglobulins/blood products: recent administration of antibody-containing blood products may interfere with the immune response to live-attenuated formulations; spacing per standard immunization guidance is advised.
Children below 2 months of age: The safety and efficacy of Encephalitis Vaccine in children younger than 2 months has not been established. No data are available.
There is no established scenario of clinically meaningful "overdose" with Encephalitis Vaccine, as it is administered as discrete, scheduled doses by a healthcare professional rather than self-administered on an ongoing basis. If an excessive dose or dosing error is suspected, or if a recipient develops any concerning symptoms after receiving Encephalitis Vaccine, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home management.
Vaccines, Anti-sera & Immunoglobulin
Store in a refrigerator (2°C-8°C). Do not freeze. Store in the original package in order to protect from light.
BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.
Advertisement
No other Imojev products are listed yet.
Advertisement